Medical Care Technologies Inc. (OTC PINK: MDCE), a leader in AI-driven diagnostic solutions, has launched a new artificial intelligence platform designed for the early detection and ongoing monitoring of basal cell carcinoma (BCC), the most prevalent form of skin cancer. The announcement was made on September 19, 2025, from Mesa, Arizona. While BCC is rarely life-threatening, untreated cases can lead to significant disfigurement, deep tissue invasion, and expensive surgical interventions. Current diagnostic approaches depend heavily on access to dermatologists—a resource that remains limited for many communities, especially in rural or underserved areas. MDCE’s new AI platform aims to bridge this gap by enabling scalable, non-invasive, and at-home screening, empowering patients to monitor their skin health proactively. The platform leverages advanced AI algorithms that analyze texture and light reflectance patterns in skin images. It identifies key visual indicators of BCC, such as irregular borders, uneven pigmentation, and unique surface textures, allowing for early recognition of suspicious lesions. By incorporating continuous longitudinal monitoring, the system can track changes over time, distinguishing between benign skin conditions and early-stage malignancies, and triggering timely alerts for medical evaluation. “BCC affects millions of people annually, yet a significant number of cases go undetected until they cause irreversible damage,” said Marshall Perkins, CEO of Medical Care Technologies Inc. “Our AI platform has the potential to transform early detection by bringing reliable, accessible screening directly into the hands of patients.” The technology is part of MDCE’s broader mission to develop AI-powered tools for preventive medicine, with current focus areas including dermatology, neurology, and ocular health. The company continues to expand its portfolio of solutions designed to improve early diagnosis and reduce healthcare disparities. Medical Care Technologies Inc. (OTC: MDCE) is listed on the OTC PINK market and maintains corporate websites at www.medicalcaretechnologies.com and www.mdcestock.com. This press release includes forward-looking statements within the meaning of federal securities laws. Actual results may differ materially due to factors such as regulatory approval, market adoption, and technological development. For inquiries, investors may contact [email protected].